The territories covered under the renewed deal include Bulgaria, the Czech Republic, Hungary, Poland, Romania and the Slovak Republic.
The non-selective, non-steroidal anti-inflammatory drugs AULIN and MESULID are offered on prescription as an oral tablet and granules for oral suspension.
Helsinn Group CEO Dr Melanie Rolli stated: “We are pleased to have signed this agreement with Angelini and honoured to maintain our ongoing collaboration.
“Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much-needed treatment.”
“This collaboration is built on a foundation of mutual trust, highlighted by our shared commitment to professional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.”
In May 2023, Angelini Pharma and JCR Pharmaceuticals signed a global development and commercialisation agreement focused on developing novel biologic therapies.
This collaboration utilises J-Brain Cargo technology to address epilepsy.
JCR Pharmaceuticals received research expense reimbursements, upfront payments and milestone payments of $505.5m, in addition to tiered royalties on net product sales post-approval.